Global Blood Therapeutics, Inc.: directors' dealings · United States · SEC (Form 4)

About Global Blood Therapeutics, Inc.

Global Blood Therapeutics, Inc. (GBT) was a United States biopharmaceutical company historically listed on the NASDAQ under the ticker GBT, before being acquired by Pfizer. For investors tracking SEC Form 4 insider activity or legacy filings, the key point is that GBT is no longer an independent publicly traded company; its business and assets were folded into Pfizer following the announced transaction in 2022. The company’s headquarters were in South San Francisco, California, placing it in one of the most important U.S. biotech clusters. ([pfizer.com](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-acquire-global-blood-therapeutics-54-billion-enhance?utm_source=openai)) Founded in 2011, GBT was built as a focused rare-disease biopharma company dedicated to discovering, developing, and delivering therapies for sickle cell disease. Its strategy was highly specialized: rather than pursuing a broad pipeline across multiple therapeutic areas, the company concentrated capital and scientific resources on hemoglobin S biology and the mechanisms that drive red blood cell sickling. That narrow focus gave GBT a clear identity in the market and made it a recognizable name in rare hematology. ([pfizer.com](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-acquire-global-blood-therapeutics-54-billion-enhance?utm_source=openai)) GBT’s flagship commercial product was Oxbryta (voxelotor), which the company described as the first FDA-approved medicine that directly inhibits sickle hemoglobin polymerization, the root cause of red blood cell sickling in sickle cell disease. The company also advanced pipeline assets including inclacumab, a P-selectin inhibitor in Phase 3 development aimed at reducing vaso-occlusive crises, and GBT601, a next-generation hemoglobin S polymerization inhibitor. These programs positioned GBT as both a commercial-stage and development-stage rare-disease company. ([pfizer.com](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-acquire-global-blood-therapeutics-54-billion-enhance?utm_source=openai)) From a competitive standpoint, GBT operated in a specialized and medically underserved market. Sickle cell disease represents a high-unmet-need therapeutic area, which historically supported premium valuation for companies able to bring differentiated science to market. At the same time, the investment case carried the usual biotech risks: regulatory uncertainty, clinical trial execution, reimbursement challenges, and concentration risk around a small number of lead assets. GBT’s eventual takeover by Pfizer underscored the strategic value of its hematology franchise and the interest of large-cap pharma in rare blood disorders. ([pfizer.com](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-acquire-global-blood-therapeutics-54-billion-enhance?utm_source=openai)) A major recent event was Pfizer’s completion of the acquisition, which ended GBT’s life as a standalone public company. For market context, the company was a U.S.-based NASDAQ-listed biotech, but any current investor analysis should treat it as a historical reference point rather than an active listed security. The legacy of GBT remains its scientific and commercial contribution to sickle cell disease treatment development. ([pfizer.com](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-completes-acquisition-global-blood-therapeutics?utm_source=openai))